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Xiaoqinglong granules (XQLG) has been shown to be an effective therapy in asthma animal models. We reviewed the literature
and conducted this study to assess the impact of XQLG as an add-on therapy to treatment with fluticasone/salmeterol (seretide)
in adult patients with mild-to-moderate, persistent asthma. A total of 178 patients were randomly assigned to receive XQLG and
seretide or seretide plus placebo for 90 days. Asthma control was assessed by asthma control test (ACT), symptoms scores, FEV1 ,
and PEF. Baseline patient-reported Chinese medicine (CM)-specific symptoms were analyzed to determine whether the symptoms
may be possible indicators of treatment response by conducting latent class analysis (LCA). There was no statistically significant
difference in ACT score between two groups. In the subset of 70 patients with symptoms defined by CM criteria, XQLG add-on
therapy was found to significantly increase the levels of asthma control according to global initiative for asthma (GINA) guidelines
(𝑃 = 0.0329). There was no significant difference in another subset of 100 patients with relatively low levels of the above-mentioned
symptoms (𝑃 = 0.1291). Results of LCA suggest that patients with the six typical symptoms defined in CM may benefit from XQLG.

1. Introduction
Complementary or alternative medicine (CAM) is extensively used in the treatment of asthma. In spite of the multitude of Western medicine treatments available for patients
with asthma [1–4], only 41% of UK asthma sufferers have not
used CAM and of those two-thirds would consider using it in
the future [5]. Recommendations for the use of CAMs should
be based only on rigorous proof of efficacy derived from

high-quality studies [6]. Chinese herbal medicines (CHMs)
are a consistently popular form of CAMs in asthma and
proprietary asthma drugs are derived from herbal remedies
[7]. Some of these herbal remedies have a millenary history
and represent the traditional medicine in many countries.
Xiaoqinglong decoction (XQLD), also known as Sho-seiryuto (SST) in Japan and So-cheong-ryong-tang (SCRT) in
Korea, was first written about by Zhang Zhong Jing, in the
Traditional Chinese Medicine (TCM) classic text Shang Han
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Table 1: Components of Xiaoqinglong granule (with sugar, 1000 g)∗ and their chinese medicine treatment functions.

Pi yin name

Latin name

Part used

Weight

Ma Huang

Ephedra sinica Stapf.

Stems

154 g

Gui Zhi

Cinnamomum cassia
Presl.

Twigs and branches

154 g

Roots
Rhizomes

154 g
154 g

Chinese medicine treatment functions
Ma Huang resolves the exterior and diffuses the lungs, stops
coughing, and levels panting.
Gui Zhi resolves the exterior and scatters cold. When
combined with Ma Huang, Gui Zhi strengthens Ma Huang’s
function of promoting diaphoresis.
Bai Shao is used to harmonize the blood to regulate qi.
Gan Jian scatter cold, dispel dampness.

Whole

77 g

Xi Xin prevents wind cold.

Roots

154 g

Mix-fried Gan Cao harmonizes the other medicinal in this
formula.

Rhizomes

231 g

Ban Xia transforms phlegm and down bears the qi.

Fruits

154 g

Wu Wei Zi engenders fluids, constrains the lung qi, and helps
stabilize panting.

Bai Shao
Gan Jiang

Paeonia lactiflora Pall.
Zingiber officinale Rosc.
Asarum heterotropoides
Xi Xin
Fr. Schm.
Glycyrrhiza
uralensis
Zhi Gan Cao
Fisch.
Pinellia ternate (Thunb.)
Fa Ban Xia
Breit.
Schisandra
chinensis
Wu Wei Zi
(Turcz.) Baill.

∗

Chinese Pharmacopoeia (2005) [12].

Lun (Treatise on Cold Damage Diseases), about 1,800 years
ago [8, 9]. There are eight herb components in the medicine.
These constituents and their actions are described in Table 1
[10, 11].
XQLD is a popular intervention which has been used for
the treatment of asthma triggered by upper respiratory infections [13]. It is most suitable when phlegm is excessive, clear,
and watery and the body feels chilly [14, 15]. Accordingly,
XQLD is not used to treat dry cough or cough with thick
or yellow phlegm [11]. Since TCM was brought to Japan and
many other Asian countries [16], XQLD has had a very great
influence on the practice of medicine. A large sample-sized
retrospective study indicates that XQLD is a very commonly
used formula in Taiwan [8, 17]. XQLD has attracted Asian
scientists with an interest in investigating mechanisms of
action since the 1980s, particularly in Taiwan [18] and Japan
[19].
1.1. A Review of the Pharmacologic and Clinical Effects of
XQLD. The general pharmacological properties of XQLD
extracts were investigated in various experimental animals
[20]. XQLD has been reported to show antiallergic effects
[21–23] and appears to be useful for treating type I allergic
reactions. There are few antihistaminic side effects, such as
the sedation and drowsiness that result from blockade of
histamine H1 and muscarinic receptors in the brain [24]. The
suppressive activity by XQLD on chemical mediators, such
as histamine and leukotrienes from peritoneal mast cells in
vitro, has also been demonstrated [23].
A previous study in guinea pigs demonstrated that
the antiasthmatic effects of XQLD appeared to be partly
mediated by stimulation of 𝛽2-adrenoceptors, leading to
broncho relaxation, and that XQLD inhibits the infiltration
of eosinophils into the airway [25]. Fresh data on asthma
has shown that at least a part of the mechanism of action of
XQLD against OVA-sensitized allergic airway inflammation
in a mouse model is different from that of prednisolone, and

the results demonstrate that XQLD alleviates nasal symptoms
by the inhibition of histamine signaling through suppression
of TDI-induced H1R and HDC gene upregulation [19].
In addition, due to the multiple components in XQLD,
there may be other mechanisms of action. For example,
XQLD appears to inhibit mast cell degranulation [26] and
influence CD4(+) T cells, which may be significant in
developing its use in the treatment of IgE-mediated allergic
asthma [16]. The role that XQLD may play in the regulation of cytokines and chemokines and the subsequent
effect on allergic airway inflammation is not known [27].
Kao and colleagues demonstrated that XQLT exhibits antiairway inflammatory, anti-airway remodeling, and specific
immunoregulatory effects in a chronic asthmatic mice model
[28]. Their results indicated that XQLD treatment alleviates
asthma-like pulmonary inflammation via suppression of
specific chemokines [29]. Since many physicians frequently
prescribe XQLD in combination with conventional Western
medicine, researchers evaluated the pharmacokinetic interactions in rats to evaluate the potential for adverse effects of
the combined therapy [30, 31].
Similarly, according an experimental study from Japan,
authors examined whether XQLD administration is affected
by a probiotic product and concluded that XQLD-mediated
anti-allergic effects are enhanced by the probiotic [32].
The XQLD constituent herbs, including Herba Ephedrae
and Herba Asari, have been reported to have cytokinemodulating effects [33]. Accordingly, XQLD has been used
not only for “symptomatic” treatment of allergic diseases
but also for “prevention.” It is important to note that the
pharmacokinetics of the ephedrine component of XQLD has
also been investigated [34, 35].
Previous clinical trials of XQLD were nonrandomized or
randomized to include a standard of care control group. In
these initial studies, XQLD was associated with a decrease in
the long-term rate of mild asthma exacerbations, improvement in asthma control, and improvements in lung function
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[13]. A previous clinical trial has also demonstrated its
potential benefits in improving quality of life in asthmatics
[36]. Unfortunately, most of the previous clinical trials on
XQLD are of poor methodological quality and therefore
XQLD remains of uncertain value in the treatment of asthma
[13]. Since XQLD remains popular for the treatment of
asthma in Asian communities, this study was conducted to
further elucidate the efficacy and safety of XQLD in the
treatment of asthma.
1.2. The Current Status of XQLD Research in Asthma. To our
knowledge, this is the largest randomized positive-controlled
trial to test XQLD in the treatment of asthma. Trial designers
were concerned about standardized intervention because
many of TCM decoctions cannot ensure reproducibility
of therapeutic effects. Xiaoqinglong granules (XQLG), a
Chinese patent medicine of the same name as XQLD, has
the same proportions of ingredients and is manufactured in
accordance with the Chinese Pharmacopoeia [12]. In Japan,
most uses of granules are based upon classical formulas.
The vast majority of the formulas from the Shang Han Lun
are particularly prominent in modern clinical use. Granules
have also become deeply integrated into healthcare in Taiwan
over the past 30 years [37]. This development was largely
stimulated by the convenience of granules for patients, along
with the fact that the governments of both Japan and Taiwan
also streamlining the process for applications exclusively
when granules products apply for classical formulas coverage
[38]. This has spurred a tremendous amount of growth and
economic investment, as well as widespread clinical use and
the experience that comes with increased use. Granules are
desirable for large scale healthcare distribution because they
are well regulated and hygienic, and they are ideal for research
because batches are consistent and traceable.
Likewise, the Chinese government maintains the registration administration mechanism that oversees TCM combination preparations originating from historic, classic, and
well-known recipes. The application data for marketing TCM
combination preparations may be partially exempted based
on formulation and source as well as their composition,
function, indications, and manufacturing procedures [39].
However, perhaps as a result of this streamlining of the
process for phase I, II, and III trials, there are certain barriers
to obtaining more specific indications and detailed safety
assessment reports of current products. High quality research
is needed in the area of efficacy and safety of traditional
Chinese herbal medications.
1.3. Chinese Medicine Patterns of Asthma. The aim of the current study, therefore, is precisely to determine the effectiveness and safety of XQLG for the treatment of asthma in adults.
In addition, the predictive value of the baseline characteristics
with respect to response to the therapy is investigated due
to the importance of clinical characteristics, as reported in
previous studies. Similarly, Chinese medicine (CM) symptoms are very important for CM diagnostics in daily clinical
practice. In CM, a specific set of symptoms is referred to
as a pattern. CM pattern classification has been used to
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define subsets of patients within a few thousand years. This
is analogous to the development of personalized medicine in
Western medicine concepts, where active research is being
conducted to define genetic or nongenetic characteristics that
predict treatment response to new or existing drugs. The
additional specific study aims are therefore to (1) use latent
class analysis, a statistical model to classify asthma adults with
symptoms predicators; (2) provide evidence of latent class
concurrent validity by examining association between class
membership and unmet healthcare needs.

2. Methods
2.1. Patients. Male and female patients (aged 18–65 year)
with a documented history of asthma as defined by the
National Institute of Health (NIH) [40] and Global Initiative
for Asthma (GINA) [41] were eligible for study entry. Other
inclusion criteria were reversibility of baseline forced expiratory volume in one second (FEV1 ) (≥15% and ≥200 mL) in
response to inhaled salbutamol, and “asthma of cold pattern”
according to Criteria of Diagnosis and Therapeutic Effect
of Disease and Syndromes in Traditional Chinese Medicine
[42]. According to the guidelines of asthma treatment and
prevention in China (GATPC) [43], patients are divided into
three types, including acute exacerbation, chronic persistent,
and clinical remission. This trial included only participants
with mild-to-moderate persistent asthma.
Exclusion criteria included the following. Contraindicated medications included theophylline, corticosteroids, and
short-acting beta2 agonist (SABA) therapy within the past
two weeks; any significant disease or disorder that may
influence results or a patient’s ability to participate in the
study; “asthma of heat pattern” according to Criteria of
Diagnosis and Therapeutic Effect of Disease and Syndromes
in Traditional Chinese Medicine [42]; women who were
pregnant or breastfeeding; known hypersensitivity to any
intervention; participation in other investigational studies in
the last 4 weeks.
The study was conducted in accordance with the Declaration of Helsinki and was approved by local ethics committees
and institutional review boards as appropriate. All patients
provided written informed consent prior to participating in
the study.
2.2. Study Design. A randomized, double-blind, positive controlled, parallel-group, multicenter study was conducted at
the six centers in China. The study, focusing on a superiority
study design, was sequentially conducted as follows: a runin period of one week prior to randomization, followed by a
treatment period of 90 days. At the end of the run-in period,
participants were randomized to the active XQLG/seretide
group (Group A) or placebo/seretide group (Group B) by
the central randomization system (Figure 1). This system is
provided by China Academy of Chinese Medical Sciences,
which adopted the computer telephone integration (CTI)
technology to integrate computers, internet, and telecom. The
random number list is assigned by interactive voice response
(IVR) and interactive web response (IWR) [44]. The success
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Assessed for eligibility ( ६ = 180)

Excluded ( ६ = 2):
Not meeting inclusion criteria ( ६ = 1)
Other reasons (६ = 1)

Randomized ( ६ = 178)

Group A (XQLG + seretide)

Group B (placebo + seretide)

Allocated to XQLG add-on group (६ = 89)
Received allocated intervention (६ = 89)

Allocated placebo add-on group (६ = 89)
Received allocated intervention ( ६ = 89)

Analyzed ( ६ = 84)
Excluded from analysis (६ = 5)
Adverse event (६ = 2)
Protocol violation ( ६ = 2)
Others ( ६ = 1)

Analyzed (६ = 86)
Excluded from analysis (६ = 3)
Lack of efficacy ( ६ = 1)
Protocol violation ( ६ = 1)
Others ( ६ = 1)

Figure 1: Flow Diagram of the enrollment progress through the phases of XQLG randomized trial of the two groups.

of blinding will be assessed at each participant’s last visit. An
assessor who did not participate in the treatment and who
is blinded to the allocation results will perform the outcome
assessment.
Sample size calculation was projected with the use of SAS
software. Based on our pilot trial, the response rate after 90
days was estimated at 75% in the conventional treatment
group and 94% in XQLG add-on therapy group (level of
significance 5%, power of 90%).

3. Treatment
3.1. XQLG
Proprietary name: Xiaoqinglong granules.
Chinese pronunciation: Xiaoqinglong Keli.
Xiaoqinglong granules (State Food and Drug Administration (China) Approval no. Z19993076) used was manufactured by Beijing Shouer Pharmaceutical Factory (Beijing,
China) (batch no. 091201).
Ingredients: Herb Ephedrae, Ramulus Cinnamomi, Rhizoma Zingiberis, Radix Asari, Fructus Schisandrae, and
Radix Paeoniae Alba (Table 1).
Quality control: Beijing Shouer Pharmaceutical Factory
is a GMP certificated pharmaceutical factory. Its product
(batch no. 091201) complies with the requirements of Chinese Pharmacopoeia 2005. According to pharmacopeia
requirement, compounds Ephedrine hydrochloride, Pseudoephedrine hydrochloride, and Paeoniflorin in Xiaoqinglong granules sample were determined (6.232 mg/g,
2.853 mg/g, and 0.8538 mg/g, resp.) and fully comply with
Chinese pharmacopeia 2005 standard. Identification details
refer to Chinese Pharmacopoeia (2005 edition).

Description: light brown to brown granule, or grey to
light brown, smells slightly fragrant, tastes sweet and slightly
pungent.
3.2. Seretide. Seretide is a combination medication containing an inhaled corticosteroid (fluticasone) and a long acting
reliever or symptom controller (salmeterol). This combination of salmeterol xinafoate and fluticasone propionate is recommended by GINA as a regular treatment for uncontrolled
asthma [41].
Subjects in the XQLG add-on group received oral XQLG
(taken after being dissolved in boiled water, 13 grams/1 pack,
three times a day) and seretide (1 puffs twice daily). Subjects
in the seretide group received xiaoqinglong placebo granules
for 90 days and seretide (1 puffs twice daily).
Subjects requiring additional intervention at any time
because of disease severity were withdrawn from the study.
For the duration of the study, inhaled Ventolin (100 to 200 𝜇g)
3 to 4 times daily, not exceeding 8 puffs (800 𝜇g/day), was
allowed as needed.
3.3. Clinical and Laboratory Evaluation. The primary outcomes were the achievement of asthma control and asthma
control evolution. Asthma control achievement was based
on clinical control (as recommended by GINA 2006) [41,
45]. Asthma control evolution was measured with the ACT
(Dutch version). The ACT is a clinically validated measure for
asthma control, consisting of five questions, each having five
possible response modalities (classified by decreasing levels
of asthma control, scored from 5 to 1) [46, 47]. The ACT
score (range 5–25) was determined by summing the response
scores to the five questions; the higher the score, the better
the asthma control. The ACT was filled out by patients at the
start of the run-in phase, at randomization and 7, 30, 60, and
90 days after randomization.
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Table 2: Two latent class models of asthma participants and relative
symptoms response probabilities.

Item types (symptom)
Qi vacuity
Chest tightness
Aversion to cold
Clear, pale, or watery phlegm
Torpid intake
Coughing
Fever
No thirst
Latent class prevalence

Rule 1
Class 1 subset
(𝑛 = 100)

Rule 2
Class 2
subset
(𝑛 = 70)

0.8903†
0.7735
0.6385
0.3927
0.3554
0.8604
0.0000
0.7481

1.0000
0.9672
0.7454
0.9984
0.6935
1.0000
0.0287
0.4588

0.5898

0.4102

Note. The model shows the different response patterns of the two rules on
different item types. Rule 1; Rule 2.
†
Item-response probabilities > .5 in bold to facilitate interpretation. Itemresponse probabilities corresponding to a yes response; Qi vacuity: shortness
of breath; chest tightness: oppression in the chest, feeling of oppression in
the chest; aversion to cold: sensation of cold which cannot be relieved by
warmth, also known as chills; clear, pale, or watery phlegm; torpid intake:
loss of appetite with no desire for food with decreased intake, the same as
poor appetite; coughing: (1) the expelling of air from the lungs suddenly
with an explosive noise or expectoration of sputum; (2) any disease mainly
manifested by cough; fever: elevation of the body temperature above the
normal or subjective feeling of feverishness; no thirst: no feeling of dryness
of the mouth with a desire to drink.

Secondary outcomes included changes in lung function
pre- and posttests (FEV1 , PEF). Asthma symptom scores,
measured on a scale of 0 to 6 (0 = no symptoms; 2 = mild
symptoms; 4 = moderate symptoms; 6 = severe symptoms),
were also recorded. These scores were summed to obtain
the total daily asthma symptom score in 7, 30, 60, 90 days.
Safety evaluations included incidence of treatment-emergent
adverse events (AEs) and serious adverse events (SAEs).
3.4. Statistical Analysis. All randomized subjects were
assessed by comparing baseline characteristics of both study
groups using unpaired 𝑡-tests for continuous variables, and
chi-squared tests or Wilcoxon rank sum test for categorical
variables. The primary analysis was performed on the
intent-to-treat (ITT) approach including all randomized
patients with a baseline value and at least 1 treatment period
measurement. The ACT scores measured at baseline and
90 days were analyzed using a repeated measures multivariate
ANOVA. Asthma control (GINA 2006) was analyzed using
Wilcoxon rank sum test at endpoint. Missing data for secondary endpoints were imputed using the Last Observation
Carried Forward method. Unless otherwise stated, results
are reported as mean ± SD. Assumptions of normality and
homoscedasticity were assessed. All statistical tests were 2
tailed, and 𝑃 values less than .05 were considered statistically
significant. The safety evaluation included all randomized
patients. The number and percentage of patients reporting
clinical adverse experiences were summarized by treatment
group.
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Table 3: Subject demographics and baseline characteristics (ITT
population).
XQLG add-on
group (𝑛 = 84)

Placebo add-on
group (𝑛 = 86)

Age, year, mean (SD)
Sex, n male (%)
BMI, kg/m2 , mean (SD)
GATPC

44.13 (12.42)
34 (40.48)
22.66 (3.22)

44.20 (11.92)
46 (53.49)
22.72 (2.83)

II
III
Duration of disease, year,
mean (minimum,
maximum)
FEV1 (%), mean (SD)
PEF, L/min, mean (SD)
ACT, mean score (SD)

45 (53.57)
39 (46.43)

44 (51.16)
42 (48.84)

10.83 (0.00,52.00) 11.24 (0.00,54.00)
75.60 (25.91)
282. 71 (135.84)
16.86 (3.67)

72.45 (22.61)
282.31 (20.92)
16.94 (3.57)

Definition of abbreviations: GATPC: guideline of asthma treatment and
prevention in China; ACT: asthma control test; ITT: intent-to-treat.

Given the identical protocols and measurements, baseline
data for Group A (Figure 1) and Group B clinical studies
were combined for the subset analyses. The latent classes were
determined based on presence or absence of 8 symptoms: Qi
vacuity, chest tightness, aversion to cold, clear, pale, or watery
phlegm, torpid intake, coughing, fever, and no thirst. Table 2
presents each of the variables and how they were categorized.
In order to examine the structure underlying the set of 8
symptoms, latent class analysis (LCA) was performed using
SAS PROC LCA (SAS version 9.2, Cary, NC, USA: SAS
Institute Inc.) [48]. LCA is a statistical method that is used
to classify subtypes of patients according to selected TCM
clinical characteristics and estimate the appropriate number
of latent classes based on the lower Bayesian information
criteria (BIC) value and the Akaike information criterion
(AIC). In PROC LCA, missing data are managed by maximum likelihood using an expectation-maximization (EM)
procedure, with data assumed to be missing at random.

4. Results
A total of 178 patients underwent randomization, of which 170
patients comprised the ITT population. Reasons for patient
withdrawal at the screening and randomization stages are
summarized in Figure 1. Nearly half of the patients were
men (47.6%), and the age ranged from 19 to 65 year. Baseline
demographics and clinical characteristics were well matched
between groups (Table 3). The subjects enrolled in this
trial had inadequately controlled asthma as defined by the
inclusion criteria of the study design and a low ACQ score
consistent with poorly controlled asthma.
4.1. Asthma Outcomes. Compared with baseline, the improvements in uncontrolled levels of asthma control according to GINA guidelines during the 90-day treatment period
were observed both in the XQLG 13 g three times daily
combination therapy and control groups (uncontrolled (%)
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Table 4: Assessment of Level of asthma control according to GINA Guidelines.

Visit

Levels of asthma control
Uncontrolled
Partly controlled
Controlled
Total
Uncontrolled
Partly controlled
Controlled
Total

0 day

90th day

XQLG add-on group (n, %)
76 (90.48)
8 (9.52)
0 (0.00)
84
5 (6.58)
41 (53.95)
30 (39.47)
76

Table 5: Asthma control test (ACT) score and asthma symptoms
score in trial visit.

ACT Score

Asthma
symptoms

Day Difference in mean change
Group A versus Group B (95% CI)
7 0.26 (−1.31 to 1.82)
30 0.20 (−1.64 to 2.04)
60 0.65 (−1.19 to 2.49)
90 0.35 (−1.49 to 2.19)
7
30
60
90

−1.09 (−3.42 to 1.24)
−0.68 (−3.39 to 2.02)
−1.42 (−4.1 to 1.25)
−1.13 (−3.83 to 1.58)

9.14

Age, year, mean (SD)
Sex, n male (%)
BMI, kg/m2 , mean (SD)
GATPC, mean score (SD)

0.1255
0.4083
0.0823
0.1728

II
53 (53.00)
III
47 (47.00)
Duration of disease, year,
12.38 ± 13.74
mean (SD)
72.76 ± 26.52
FEV1 (%), mean (SD)
PEF, L/min, mean (SD)
287.6 ± 140.07

0.8883

36 (51.43)
34 (48.57)

0.8405

9.13 ± 10.52

0.2448

75.84 ± 20.73
275.3 ± 117.32

0.7313
0.4194

32.61

11.54

FEV1 %

0.5470

Class 1 subset Class 2 subset P value
(𝑛 = 100)
(𝑛 = 70)
43.67 ± 12.61 44.87 ± 11.46 0.5462
0.2199
51 (55.00)
29 (41.43)
22.86 ± 3.39
22.46 ± 2.40 0.4990

0.5914
0.7166
0.2485
0.5334

10

1

P value

Table 6: Subject demographics and baseline characteristics of class
1 and 2 subset (𝑛 = 170).

P value

100
23.28

Placebo add-on group (n, %)
80 (93.02)
6 (6.98)
0 (0.00)
86
9 (11.25)
38 (47.50)
33 (41.25)
80

PEF %

XQLG add-on group
Placebo add-on group

Figure 2: Adjusted mean change from baseline in forced expiratory
volume (FEV1 %) and peak expiratory flow (PEF%) during the entire
90-day treatment period.

from 90.48 to 6.58, from 93.02 to 11.25, resp.). However,
no statistically significant difference between treatment
groups was apparent (𝑃 values 0.8883) (Table 4), whilst
significant amelioration of the predefined scores was seen
in both groups. Similarly, although all treatment groups
demonstrated a mean improvement in ACT score and asthma
symptoms (Table 5), between-treatment differences were also
not statistically significant. Estimated mean differences were
0.35 (95% CI, −1.49 to 2.19; 𝑃 = 0.5334) and −1.13 (95%
CI, −3.83 to 1.58; 𝑃 = 0.1728), respectively, for 90-day
evaluation of ACT Score and Asthma Symptoms. Overall,
the improvements in ACT score and asthma symptoms with

XQLG were paralleled by significant improvements in control
group scores for 7 days, 30 days, 60 days, and 90 days (all
𝑃 > 0.05).
Throughout the study period, the mean change from
baseline in FEV1 % increased for all treatment groups; at
the end of the 90-day treatment period, FEV1 % increased
to 9.14% in XQLG add-on therapy and 11.54% for seretide.
There was no statistically significant difference between the
groups (Figure 2). The mean improvement in PEF% showed
no between-treatment differences between the XQLG and
control groups.
LCA grouped all individuals into 2 classes (groups)
according their symptoms. To determine the presence of
latent classes for symptoms, 1 and 2 class models were tested.
As shown in Table 2, item-response probabilities >0.5 in bold
were defined to facilitate interpretation in a 2-class model.
Class 1 consisted of 58.98% (𝑛 = 100) of the sample. As can
be seen in Figure 3, the symptoms trend of adherence was
similar in both classes. These participants were consistent in
their responses to cold pattern symptoms. Class 2 consisted
of the remainder 41.02% (𝑛 = 70) of the sample. Compared
with participants assigned to class 1, class 2 participants
had a higher probability of reporting adherence to the six
typical symptoms, including Qi vacuity; chest tightness;
aversion to cold; clear, pale, or watery phlegm; torpid intake;
coughing. Conditional probabilities are provided in Table 2
and represented in Figure 3. Analyses were conducted to
compare characteristics of class 1 to class 2 participants
(Table 6). Duration of disease, age, gender, FEV1 (%), or PEF
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Table 7: Assessment of levels of asthma control according to GINA guidelines in class 1 and class 2 subset of participants.
0 day
Mean
Partly
Uncontrolled
Controlled score
controlled

P value

90th day
Mean
Partly
Uncontrolled
Controlled score
controlled

P value

Class 1
XQLG add-on group
Placebo add-on group

47
44

5
4

0
0

50.80
50.16

0.8292

6
5

30
20

16
23

46.67
54.64

0.1291

29
36

3
2

0
0

36.28
34.84

0.5173

2
8

15
20

15
10

40.65
31.15

0.0329

No thirst

Fever

Coughing

Torpid intake

Clear, pale, or
watery phlegm

Aversion to cold

4.2. Safety. Overall, treatment with XQLG and seretide was
well tolerated. Neither group showed abnormal findings in
hematology, or serum chemistry tests. No serious adverse
effects were observed in either group. In particular, there were
no deaths, hospitalizations, or emergency room visits. A total
of one AE was reported by one patient (0.9%) in the XQLG
add-on group with mild sinus tachycardia, which was of mild
intensity, did not necessitate treatment discontinuation, and
was not deemed to be treatment related by the investigator.

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Chest tightness

(%) did not appear to impact class membership. Even though
there was a trend for amelioration of FEV1 in the XQLG addon group, no significant differences were found. In the subset
of 70 patients with the above-mentioned typical symptoms,
XQLG add-on therapy was found to significantly increase the
levels of asthma control according to GINA guidelines (𝑃 =
0.0329) (Table 7). There was no significant difference in the
increase in the levels of asthma control between Groups A and
B in the remaining subset of 100 patients with relatively low
sensitivity of the above-mentioned symptoms (𝑃 = 0.1291)
(Table 7).

Qi vacuity

XQLG add-on group
Placebo add-on group

Probability of asthma

Class 2

Syndrome
Class 1,58.98%
Class 2,41.02%

Figure 3: Conditional probabilities for each item endorsement
according to latent class for asthma participants in subjects (𝑛 =
170).

5. Discussion
The last decade has seen an increased interest in the use
of TCM for asthma treatment, and effects have been documented in numerous conditions. Since 2005, several controlled clinical studies of “antiasthma” herbal remedies have
been published in SCI indexed journals [49, 50]. XQLD has
played an important role in preventing and treating lung diseases in China and other Asian countries for centuries where
it is still used as a monotherapy or in integrated medicine.
Such a wide spectrum of clinical efficacy suggests that the
power of XQLG add-on therapy may help restore lung
function. However, well-controlled clinical trials using herbs
for the treatment of asthma are rare.
Using our randomized, double-blind, positive controlled,
parallel-group design, we demonstrate that XQLG add-on
therapy to seretide can significantly increase baseline levels of asthma control according to GINA guidelines ACT
score, asthma symptoms score, FEV1 , and PEF in asthmatic
subjects. However, there were no differences between XQLG
and control groups at the 90-days assessment. These findings
are not completely consistent with the results of previous

trials [13]. According to the published literature, some trials
have identified significant differences in responses between
XQLD add-on therapy and conventional western medicines
although both of them were obviously better than baseline.
Additionally, FEV1 and PEF were significantly better than
conventional western medicines groups. In contrast, the
data we obtained in the current study showed no clinically
significant difference in the above parameters when XQLG
was added to seretide, compared to when placebo was added.
Thus it is necessary to include precise traditional criteria into
the inclusion criteria of clinical studies on traditional herbal
combinations.
The associations observed in this study must be viewed
with a number of considerations. A possible interpretation
of no clinically significant differences for the overall control
of asthma may not take into account that certain specific
characteristics of asthma control may in fact show clinically
significant improvements, some of which may not be primary
endpoints and may impact quality of life, such as days where
normal activity is limited due to asthma symptoms, or visits
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to the emergency department or hospital. Some of these are
included in the evaluation of a total asthma control symptom
score, but these scores are frequently not broken down in
clinical trials. Moreover, analysis of the entire group as a
whole may not take into consideration that some patients
with certain symptom patterns may in fact show a higher level
of improvement if analyzed separately. A larger study will
allow for stratification of patients into different groups based
on age, socioeconomic status, gender, and so forth. In our
case, screening patients with symptoms that CM identifies
as important in asthma status may help to identify response
to specific treatments in specific groups. The magnitude of
pattern effect in a TCM clinical trial is often calculated as
the benefit in the TCM arm relative to the benefit in the
control arm. According to the Chinese Pharmacopoeia (2005
edition) [12], indications of XQLG include wind-coldretained fluid pattern manifested as aversion to cold, fever,
absence of sweating, wheezing, and cough with watery
phlegm. In fact, our study demonstrates that if those patients
with TCM symptoms can be separated out using latent class
analysis, the effect of XQLG may be statistically significant
when compared to placebo in this study.
Comparative latent class analysis is a statistical method to
define symptom patterns for the purposes of distinguishing
certain patient groups. This method was used in this study to
analyze in greater depth the efficacy of the XQLG treatments.
The determination of what treatment is best for what kinds of
patients is a general objective of clinical research [51]. One
major factor is the application of the LCA in an effort to
determine which treatment is preferable for which kind of
patients. Interestingly, results indicate that all the subjects can
be classified into two distinct subsets according to the conditional probabilities of asthma participants found in the LCA.
The symptom trend was similar in both classes, but there
were clear differences. The subtype of 70 participants had
a higher probability of reporting adherence to the six typical
symptoms, including Qi vacuity, chest tightness, aversion
to cold, clear, pale, or watery phlegm, torpid intake, and
coughing. When this group was analyzed separately for the
comparative efficacy of XQLG versus placebo add-on therapy,
significantly increased levels of asthma control were found
in the former group (𝑃 = 0.0329) [9]. The implications of
this finding is that one may be able to use TCM symptom
pattern recognition to study and subsequently identify in
clinical practice those patients who may respond optimally
to a specific herbal treatment.
There were no serious adverse events and side effects were
insignificant, in line with other similar studies [13]. XQLG
intervention appears to be a safe mode of therapy in our
patient study group. However, in the United States, XQLD is
not available from a pharmacy or via a doctor’s prescription
because this formula includes an illegal herb ephedra [52].
New evidence indicates that rational use can avoid the toxicity
of ephedra [52]. It is important to note that ephedra must
always be prescribed with care and the safe use of a combination of western medical remedies with herbal therapy should
result from the evaluation of drug-herb interactions.
We strictly defined TCM indications in inclusion criteria.
All subjects were characterized as TCM cold pattern by
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using the strict predefined criteria. However, we almost
certainly underestimated pattern classification accuracy by
using current criteria. If other TCM classifications of asthma
are included, the results may be different [53, 54].
This study has other limitations. First, our subtype population was relatively small (class 1 = 100; class 2 = 70). Second,
the use of multiple single-item symptom measures raises
questions regarding reliability and validity. In the design of
clinical trials on herbal remedies, a selection of only a few of
the multitude of symptoms that asthma patients experience
are evaluated. In this study, “asthma of cold pattern” according to current criteria of diagnosis and therapeutic effect of
disease and syndromes and the diagnosis mild-to-moderate
asthma might not suffice.
Despite these limitations, this study makes an important
contribution to impact assessment of symptoms on the
treatment efficacy in asthma patients. As we look toward
future generations of TCM asthma trials, the concept of
individualized therapy based on predictive symptom markers
to better select patients who would benefit from a specific
intervention is likely to be integral. A recent perspective on
considering inclusion and exclusion criteria for randomized
controlled trials (RCTs) may integrate genotype through
characteristic symptoms [55]. It shows how meaningful stratification based on symptomatology may be, and how careful
selection of patients for targeted therapies may be of utmost
importance for developing future treatment strategies.
Further assessment is warranted of the role of XQLG in
adult asthmatic patients with six TCM typical symptoms.
If reproducible, these results provide support for designing
interventions aimed at more definite symptoms in the millions of patients currently treated for asthma.

6. Conclusions
The addition of XQLG to existing treatment using combination inhaled corticosteroid/long acting beta-agonist
(LABA) therapy did not demonstrate a statistically significant
improvement over placebo add-on therapy. However, latent
class analysis of Chinese medicine symptom patterns was able
to define a subset of patients who would respond to XQLG
add-on therapy significantly better than placebo. XQLG may
therefore be effective in the treatment of a subgroup of
asthma patients and additional studies should be conducted
to investigate efficacy and safety of this herbal medication as
first line therapy for asthma. This study also illustrates the
importance of elucidating ways of defining selective patient
populations with favorable response to specific treatment
modalities.

Abbreviations
ACT:
AE:
CAM:
CHM:
GATPC:

Asthma control test
Adverse event
Complementary or alternative medicine
Chinese herbal medicine
The guideline of asthma treatment and
prevention in China

Evidence-Based Complementary and Alternative Medicine
H1R:
HDC:
ITT:
IVR:
IWR:
LCA:
RCT:
SAE:
SCRT:
SR:
SST:
TDI:
XQLD:
XQLG:

Histamine H(1) receptor
Histidine decarboxylase
Intent-to treat
Interactive voice response
Interactive web response
Latent class analysis
Randomized controlled trial
Serious adverse event
So-cheong-ryong-tang
Systematic review
Sho-seiryu-to
Toluene-2,4-diisocyanate
Xiaoqinglong decoction
Xiaoqinglong granules.

Conflict of Interests
The authors declare that they have no conflict of interests.

Authors’ Contribution
Q. Zha, S. Lin, and C. Zhang contributed equally to this work.

Acknowledgments
This study is supported by The National Eleventh Five-Year
Support Project of China (2006BAI08B02-2). This research is
partly sponsored by the projects from the National Science
Foundation of China (30825047).

References
[1] C. Chang, “Asthma in children and adolescents: a comprehensive approach to diagnosis and management,” Clinical Reviews
in Allergy and Immunology, pp. 1–40, 2011.
[2] S. Louie, B. M. Morrissey, N. J. Kenyon, T. E. Albertson, and M.
Avdalovic, “The critically Ill asthmatic-from ICU to discharge,”
Clinical Reviews in Allergy and Immunology, pp. 1–15, 2011.
[3] A. A. Zeki, N. J. Kenyon, K. Yoneda, and S. Louie, “The adult
asthmatic,” Clinical Reviews in Allergy and Immunology, pp. 1–
18, 2011.
[4] R. R. Vatti and S. S. Teuber, “Asthma and pregnancy,” Clinical
Reviews in Allergy and Immunology, vol. 43, no. 1-2, pp. 45–56,
2012.
[5] C. E. Clark, E. Arnold, T. J. Lasserson, and T. Wu, “Herbal
interventions for chronic asthma in adults and children: a
systematic review and meta-analysis,” Primary Care Respiratory
Journal, vol. 19, no. 4, pp. 307–314, 2010.
[6] G. Passalacqua, P. J. Bousquet, K. H. Carlsen et al., “ARIA
update: I-systematic review of complementary and alternative
medicine for rhinitis and asthma,” The Journal of Allergy and
Clinical Immunology, vol. 117, no. 5, pp. 1054–1062, 2006.
[7] X. M. Li, “Traditional Chinese herbal remedies for asthma and
food allergy,” The Journal of Allergy and Clinical Immunology,
vol. 120, no. 1, pp. 25–31, 2007.
[8] F. P. Chen, F. J. Chen, M. S. Jong, H. L. Tsai, J. R. Wang, and S. J.
Hwang, “Modern use of Chinese herbal formulae from ShangHan Lun,” Chinese Medical Journal, vol. 122, no. 16, pp. 1889–
1894, 2009.

9
[9] Z. Zhang, C. Mitchell, Y. Feng, and N. Wiseman, Shang Hán
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